This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

Oncotype DX for Colon Cancer

Oncotype DX for Colon Cancer | Genomic Health, Inc.

Providing a Clearer Picture of Colon Cancer Recurrence Risk

The Oncotype DX® colon cancer test allows doctors and patients to make a more informed decision about whether or not chemotherapy is needed following surgery (stage II) or whether or not oxalipatin should be added to the chemotherapy regimen after surgery (stage III). In this way, the test may help some patients avoid the complications of treatments they do not need, while directing others to the therapy that is most likely to benefit them. The Oncotype DX colon cancer test is supported by three rigorous clinical validation studies confirming the test’s ability to provide additional and independent value beyond the currently used measures for determining colon cancer recurrence risk.

For more information, please visit our U.S. website for the Oncotype DX Colon Recurrence Score

Learn more about Genomic Health